What Lipantil Nano Treats: Main Uses and Benefits

Lipantil Nano is a prescription medication utilized in the management of elevated lipid levels in the bloodstream. Its primary therapeutic application is as an adjunct to a controlled diet and other non-pharmacological treatments, such as routine physical activity and weight reduction.

The medication is indicated for adult patients with:

• Severe hypertriglyceridemia: This involves significantly high concentrations of triglycerides, a type of fat in the blood, which can pose a health risk.
• Mixed hyperlipidemia: This refers to a combination of high serum cholesterol and high triglycerides.

In cases of mixed hyperlipidemia, Lipantil Nano is used when a statin medicine is not tolerated or is otherwise contraindicated. It may also be administered alongside a statin in patients who are at an increased cardiovascular risk and whose triglyceride and High-Density Lipoprotein (HDL) cholesterol levels are not adequately controlled by the statin alone. The therapeutic goal is to help achieve and maintain desirable blood lipid concentrations.

Quick Facts

• Therapeutic Domain: Management of high blood fat levels (dyslipidemia).
• Primary Indications: Treatment of severe hypertriglyceridemia and mixed hyperlipidemia.
• Usage Context: Employed as an adjunct to dietary modifications, weight management, and physical activity.
• Benefit: Aids in the reduction of elevated triglycerides and other blood lipids.

Lipantil Nano (fenofibrate) is a prescription medicine for use only in adult patients. Eligibility for its use is strictly determined by organ function, allergic history, and specific disease conditions, as established by regulatory authorities.

Populations Who Must Not Use Lipantil Nano (Contraindications)

Official labeling requires that the medicine must be avoided by individuals with the following absolute contraindications:

• Severe Renal Impairment: Including patients with an estimated GFR < 30 mL/min/1.73 m^2.
• Active Liver Disease: Including those with primary biliary cirrhosis or unexplained persistent liver function abnormalities.
• Pre-existing Gallbladder Disease or Chronic/Acute Pancreatitis (unless the pancreatitis is caused by severe hypertriglyceridemia).
• Known Hypersensitivity: To fenofibrate, fenofibric acid, or related compounds, including a history of photoallergy to fibrates or ketoprofen.
• Nursing Mothers (Lactation).

Eligibility-Related Restrictions

The officially documented interaction patterns for Fenofibrate, the active ingredient in Lipantil Nano, involve specific restrictions and requirements when used alongside certain drug classes and substances, as established by government regulatory authorities.

Drug-Drug Interactions

The regulatory profile highlights two types of significant interactions:

• Pharmacodynamic Potentiation: Co-administration with HMG-CoA Reductase Inhibitors (Statins) or Colchicine carries an increased, additive risk of muscle toxicity, including myopathy and rhabdomyolysis. Use with other fibrates is restricted due to a similar, severe risk of muscle damage.
• Anticoagulant Effect Enhancement: Fenofibrate potentiates the effect of coumarin anticoagulants (e.g., Warfarin), which results in the prolongation of the Prothrombin Time/INR and an increased potential for bleeding.

Pharmacokinetic and Timing Constraints

The drug's interaction profile includes requirements for specific administration timing and considerations regarding metabolic pathways and patient populations:

• Metabolic Impact: Fenofibric acid is documented as a mild-to-moderate inhibitor of CYP2C9. This pharmacokinetic effect may increase the systemic exposure of other co-administered medicines that are substrates of this enzyme.
• Timing Rule: To prevent a reduction in absorption, Fenofibrate must be administered at least 1 hour before or 4 to 6 hours after the intake of bile-acid binding resins (e.g., Cholestyramine).
• Renal Function Note: The risk of severe interactions, such as muscle toxicity with statins, is documented as being increased in patients with impaired renal function. This is due to reduced clearance and resulting accumulation of the active ingredient.
• Substance Note: Regulatory documents cite heavy alcohol use as a substance linked to liver disease, which may compound the hepatotoxicity risk associated with the medicine.

Fenofibrate's active metabolite, fenofibric acid, modulates lipid metabolism primarily through agonism of the Peroxisome Proliferator-Activated Receptor alpha ( PPARalpha), a nuclear transcription factor active in the liver and muscle. Activation of PPARalpha initiates transcriptional changes, leading to the upregulation of genes like LPL (Lipoprotein Lipase) and the downregulation of the inhibitor ApoC-III. This coordinated dual action increases the rate of VLDL and chylomicron catabolism in the plasma, resulting in a physiological decrease in plasma triglyceride levels. Concurrently, PPARalpha activation influences the genes encoding ApoA-I and ApoA-II, structural proteins of High-Density Lipoprotein ( HDL-C). This process modulates reverse cholesterol transport, which results in increased circulating HDL-C concentrations and modifies the LDL particle phenotype toward a less dense form that exhibits altered catabolism.

How to Use Lipantil Nano

The administration of Lipantil Nano (fenofibrate nanoparticle tablet) is governed by official instructions detailing the required route, standard dose ranges, frequency, and specific conditions for intake, as defined by regulatory authorities.

Official Administration Guidelines

The fenofibrate nanoparticle tablet is administered as a single daily dose to establish and maintain consistent blood levels. The recommended dose for patients with mild to moderate renal impairment (eGFR 30 to <60 mL/min/1.73m^2) requires a formal reduction to an initial dose of 48 mg or 54 mg once daily, followed by careful monitoring. However, use is formally contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73m^2). For geriatric patients, dose selection is based primarily on an evaluation of their underlying kidney function. Safety and efficacy for the pediatric population have not been established, and use is generally not recommended in those under 18 years of age.

Lipantil Nano: Recent Clinical Evidence

Evidence for Lipid Biomarkers and Dyslipidemia

Research exploring the evaluation of fenofibrate on blood fats has been a focus of short-term Randomized Controlled Trials (RCTs). These studies investigated measured outcomes related to circulating lipid biomarkers in adults diagnosed with primary hypercholesterolemia, mixed dyslipidemia, or severe hypertriglyceridemia. Trials present research reports describing measured changes in lipid biomarkers in the studied populations, often monitoring the achievement of certain lipid concentration targets. The long-term clinical relevance of these shifts is addressed through separate research approaches, and the evaluation of outcomes related to the risk of complications, such as pancreatitis, is not fully established by controlled trials.

Findings from Long-Term Cardiovascular Outcome Studies

The question of whether measured lipid outcomes relate to long-term clinical events has been studied for many years through large, pivotal trials, such as the FIELD and ACCORD-Lipid trials. These long-term studies were designed to assess outcomes related to Major Adverse Cardiovascular Events (MACE). The largest studies generally reported that the medicine was not observed to show a difference for the long-term outcomes of MACE in the full study group compared to control groups. However, subsequent subgroup analyses did describe patterns where a fewer number of cardiovascular events were observed in specific patients with notably high triglycerides and low HDL-C levels. The evidence base reported no difference for the primary composite endpoint in the overall trial populations.

Research Gaps and Uncertainty

The evidence base regarding the measurement of lipid biomarkers has been developed, but key uncertainties remain regarding the long-term clinical benefits. Cardiovascular assessment results were observed in some studies to be dependent upon specific subgroup findings, which carry inherent research limitations. Furthermore, research data remain insufficient for certain patient groups, particularly children or adolescents, and the long-term effects on specific microvascular conditions were not the primary focus of the initial trials.

Key Studies & References

1. Label: FENOFIBRATE tablet (Includes clinical study results, indications, and limitations on cardiovascular efficacy)
2. Public Assessment Report Scientific discussion Fenogal 160 mg hard capsules (fenofibrate) (Covers formulation characteristics and EMA regulatory view)

Common questions about Lipantil Nano (FAQ)

Q: Can I use this drug if I am pregnant?

Official regulatory documents indicate that this medicine is generally not recommended for use during pregnancy. There is limited data available on its use in pregnant women. The official product information states that it should only be considered for use if the potential benefits are judged by a healthcare provider to clearly outweigh the potential risks to the developing fetus.

Q: Is it safe to use this medication long-term?

When used for Restless Legs Syndrome, long-term use may be associated with a phenomenon called 'augmentation,' which is mentioned in the regulatory warnings. Augmentation means that your restless legs symptoms might worsen, occurring earlier in the day or becoming more intense. The product information includes a recommendation that patients should be monitored for this potential effect during extended treatment.

Q: Can children 2 years old use this drug for restless legs syndrome?

According to the official product labeling, this drug is not indicated for the treatment of Restless Legs Syndrome in children. The therapeutic indication specified in the regulatory documents is for use in adults with moderate-to-severe primary Restless Legs Syndrome. The official labeling does not include indications for use in children for this condition.

How to Store and Dispose of Lipantil Nano?

The storage conditions for Lipantil Nano 145 mg film-coated tablets are established to maintain the product's stability and efficacy.

Storage Requirements

The tablets must be stored at a temperature at or below 30 °C. It is important to keep the medicine in its original container to ensure protection from moisture and light. The official labeled shelf-life of the product is 3 years. As a mandatory safety measure, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired product and related waste material must be disposed of in accordance with local requirements. The product should not be flushed down the toilet or poured into a drain; it should be returned to a pharmacist or proper collection point for safe disposal.